Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Notes to Editors Morphotek’s Pipeline: Clinical Stage Phase I Product Name/Code MORAb-003 MORAb-009 Preclinical (IND preparation) MORAb-004 Humanized IgG1 antibody Pancreatic/ Lung cancer Melanoma/ Neovascular disease Preclinical (IND preparation) MORAb-022 MORAb-028 MORAb-047 MORAb-048 Fully human IgG1 monoclonal antibody Autoimmune diseases Fully human IgM monoclonal antibody Metastatic melanoma Therapeutic antibody Infectious disease Therapeutic antibody Infectious disease Phase I/II Preclinical Preclinical Preclinical Target Disease Description/Mode of Action Humanized IgG1 antibody Ovarian cancer IgG1 antibody Eisai’s Oncology Pipeline: Clinical Stage Product Name/Code Description/Mode of Action Target Cancer Preparing for Subpart H submission E7389 Microtubule growth suppressor Breast, Non-small Cell Lung, Prostate, Ovarian, Sarcoma E7070 E7820 E7080 E7974 E7107 Cell cycle G1 phase targeting agent Small Cell Lung Anti-angiogenesis agent Various Phase I Phase I Phase I Phase I Phase I in preparation Anti-angiogenesis agent Various Hemiasterlin type tubulin polymerization inhibitor Various Anti-tumor agent derived from fermentation Various Major Technology Platform of Morphotek: Fully-human monoclonal antibody generation and optimization (Human MORPHODOMA®, LibradomaTM) About Human MORPHODOMA® Human MORPHODOMA® is able to generate fully human monoclonal antibodies. Furthermore, through the application of its proprietary technology and know-how, Morphotek is able to optimize the titer of its cell-lines, effect class switching, and enhance antibody affinity. About LibradomaTM TM ® The Libradoma technology process utilizes Human MORPHODOMA and other propriety technologies to generate libraries potentially comprised of thousands of hybridomas that can be rapidly screened using high-throughput robotics to identify hybridomas expressing human antibodies with target affinity profiles. 4